Micromet, Inc. (NASDAQ: MITI) a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that it has achieved a milestone under its collaboration agreement with Bayer Schering Pharma AG.  The milestone was triggered by Micromet’s achievement of pre-clinical proof of concept for a BiTE antibody for the treatment of solid tumors. For more information, please read the complete press release